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Background. MotherSafe is a free telephone counselling service for exposures during 
pregnancy and breastfeeding. As the last health professional seen prior to consumption of 
medicines, community pharmacists’ opinion on the use of medications in 
pregnancy/breastfeeding is likely to be particularly sought by women presenting in pharmacies. 
However, a recent qualitative study revealed that community pharmacists feel unsupported in 
their role as medicine information providers to pregnant/breastfeeding women.  
Aim The aim of the current study was to undertake a descriptive analysis of calls made by 
pharmacists or pharmacist referred patients to MotherSafe across the time period 2000-2018.  
Materials and Methods A retrospective, descriptive study was conducted of call data from 
January 2000 to December 2018.  Aggregate data was examined by type of caller, reason for 
call, pregnancy category and exposure type.  
Results Most calls (57%) related to pregnancy or breastfeeding (39%) with calls equally 
distributed throughout gestation. Calls regarding potential pregnancy exposures to 
uncategorised drugs were the most frequent (mainly complementary medicines).  Unlike 
pharmacists, calls from pregnant consumers referred by pharmacists were also frequently 
regarding category A drugs.  
Conclusions 
This study highlights the need for reliable evidence-based information sources regarding the 
use of prescribed medications, over the counter and complementary preparations during 
pregnancy and breastfeeding.  There is a need for better education of pharmacists about 
appropriate information sources and the need to use evidence–based resources other than the 
A-X categories to advise their clients about the safety or otherwise of medications in pregnancy 
and breastfeeding.  
  
Introduction  
In 2018, there were around 90,000 births in New South Wales (NSW), Australia 1. While  the 
overall birth rate has declined, more women aged over 35 years are giving birth and the average 
age of first pregnancy has also been steadily rising 2. The rate of pre-existing and gestational 
conditions increases with maternal age and thus there will be more pregnant women with 
conditions such as hypertension and diabetes (e.g. 8.2/1000 pregnant women have pre-existing 
hypertension, and 7.3/1000 report pre-existing diabetes) 2. Appropriate treatment of chronic 
conditions is generally recommended to optimise perinatal outcomes. Almost 80% of pregnant 
women will also experience common pregnancy symptoms such as nausea, back pain, 
constipation, and insomnia or non-pregnancy related conditions such as cold, flu and allergies 
for which medications may be required 3-5. However, common concerns about birth defects and 
the general lack of clarity around safety leaves many women uncertain about medication use 
in pregnancy 6.  This highlights the importance of accessible and accurate information 
provision through health professionals and medicine information centres in decision making 
about medication use by pregnant women 4. Indeed studies report that up to 80% of pregnant 
women perceive a high level of need for information about medication use in their condition 7 
with higher information needs in women who are primiparous, have lower health literacy or 
use several medications, herbal or over the counter products. 5. Results of a multinational 
survey of ~7000 pregnant women identified the preferred sources of information were 
physicians, pharmacists, nurses and the internet 7. 
Community pharmacists are some of the most accessible and highly trusted 8 health 
professionals in the primary health care space and are often the last professional to be consulted 
prior to consumption of medicines. Seen as medication experts by the public, their opinion on 
the use of medications in pregnancy/breastfeeding is likely to be particularly sought by women 
who are presenting in pharmacies to purchase over the counter medicines, prescription products 
or complementary medicines.  
In a recent qualitative exploratory study with community pharmacists in NSW 9, findings 
suggested that pharmacists feel unsupported in their role as medicine information providers to 
pregnant/breastfeeding women. Pharmacists who participated in this study admitted adopting 
a highly cautious approach when counselling pregnant women on medication use and reported 
increasingly relying upon telephone support services. The study concluded that community 
pharmacists should be upskilled, better supported and encouraged to play active roles in 
providing maternal care. 
One of the major supports needed and used by participating pharmacists in the aforementioned 
study was MotherSafe. In NSW, MotherSafe is the main source of specialised information 
about medication use in pregnancy and breastfeeding for both health professionals and 
consumers. MotherSafe was established in January 2000 as a state-wide teratogen information 
service. Modelled on similar services around the world, it is a free-of-charge, telephone-based 
service, staffed by trained healthcare professionals (pharmacists and doctors), providing 
evidence-based counselling about exposures during pregnancy and breastfeeding. To better 
address future information needs and support for pharmacists who often call while their patient 
is in the pharmacy requesting information, it is important to analyse the pattern of calls made 
or referred by pharmacists. Such analysis can provide direction about workforce requirements, 
training and sourcing information for frequently called about medications/products by agencies 
and the clear information needs of MotherSafe users. Conducting this calls audit over the period 
since this service has been offered can also highlight key trends or shifts in information needs. 
The aim of the current study was to undertake a descriptive analysis of calls made by 
pharmacists or pharmacist referred patients to MotherSafe across the time period 2000-2018.  
 
Materials and Methods  
A retrospective, descriptive study was conducted to examine Mothersafe call data for the 19-
year period from January 2000 to December 2018.  
Data from calls made to MotherSafe, are entered into the MotherSafe database by the 
counsellors as they are received. The service runs in office hours Monday to Friday and the 
time each call is received is not recorded in the database.  Urgent after-hours queries are 
referred to the Poisons Information Centre which is a 24-hour service and callers are also 
advised to look at the Mothersafe website which includes factsheets which may be of assistance 
for some more common exposures and scenarios. Minimum data collected include: date of call, 
caller name, caller type (eg. Consumer- pregnant woman/partner or healthcare professional- 
pharmacist, midwife etc), maternal age, infant age, postcode and telephone number, reason for 
call (ie pregnant, planning pregnancy or breastfeeding) and the exposure of concern. An 
exposure is defined as contact, ingestion, inhalation or injection of a prescribed or over-the-
counter (OTC) medication, radiation, chemical, substances, infection or food. Exposures are 
grouped into one of 40 categories based on their general class. Callers might mention several 
potential exposures at each call, and these are listed separately. 
Aggregate data for the number of calls and individual enquiries received by MotherSafe were 
extracted for the 19-year period 2000 to 2018 and examined in a retrospective, descriptive and 
non-identifiable manner for: (1) calls from consumers who were referred by pharmacists to the 
service; (2) calls from pharmacists. General enquiries “with no specific named exposure” were 
excluded.   
Information from the MotherSafe database was reviewed for spelling mistakes and omitted 
details during data entry. Subsequently, manual data analysis of reason for call, pregnancy 
category (A, B1-3, C, D, X or Unclassified under Product Information in MIMS, an Australian 
drug reference system) and exposure type was performed using Microsoft Excel.  
The study was approved by South East Sydney Illawarra Area Health Service's Human 
Research Ethics Committee, reference number 07/131. 
Results 
In total, MotherSafe received 315,158 telephone enquiries during the period 2000 – 2018. Of 
these, 10,853 were from pharmacists or patients referred by pharmacists. Of these, 7,253 
(66.8%) were directly from pharmacists whilst the remainder were from patients who were 
asked to call MotherSafe themselves. In total, 5,925 (56.6%) were related to pregnancy, 4,122 
(39.4%) were regarding breastfeeding and 425 (4.1%) related to pregnancy planning.  
While MotherSafe is a NSW service, 185 calls (approximately 1.8% of all calls) came from 
interstate and another 154 calls (1.5%) were from the ACT. Generally these calls were dealt 
with directly at the time of the call but callers are advised  that for more complex or ongoing 
cases and for future calls Drug Information services located in the caller’s State or territory 
should be contacted 10.  
Data relating to stage of pregnancy was also available for some calls from pharmacists (2474 
calls). For calls regarding pregnancy, the median (IQ) gestational age was 18 (10 – 28) weeks; 
31% related to medication use in the first trimester, 38% in the second and 31% in the third 
trimester. Figure 1 illustrates the number of enquires by year according to whether they were 
initiated by a pharmacist or patient. In summary, the number of enquiries has plateaued since 
the steady increase of the initial years of MotherSafe.  
When calls by pharmacists were further refined to those specifically relating to exposures 
during pregnancy, it was clear that the overwhelming number of calls related to exposures to 
uncategorised drugs.  While it is important to emphasise that the ADEC categories are not 
relevant to breastfeeding, reservation about using a drug in a pregnancy category may extend 
to use in breastfeeding in consumer perception. Hence, it is interesting to note that the calls 
concerning breastfeeding exposures were more evenly distributed across pregnancy categories.  
Frequently the calls by pharmacists and patients referred by pharmacists refer to more than one 
exposure. While 72% of calls by pharmacists relate to only one exposure, referred patients will 
frequently mention several exposures (45%).  
When all queries are considered, the calls made by pharmacists differ when the patient is 
pregnant compared to breastfeeding (Table 1). Queries relating to pregnancy exposures to 
topical medicines dominated but were rarely a cause of concern during breastfeeding while 
exposures to antihistamines, antibiotics and CNS agents dominated breastfeeding related calls. 
Table 2 compares the number of enquires by medication risk category according to contact by 
a pharmacist or patient. Of note almost twice as many patients sought more advice regarding 
medications with risk category A compared to pharmacists themselves.   
Postcodes were obtained from most calls with approximately 60% coming from metropolitan 
Sydney. There were some differences in the types of calls from metropolitan versus non-
metropolitan locations eg. more calls from pharmacists in metropolitan Sydney concerned 
complementary medicine use during pregnancy and more calls were related to antidepressant 
and CNS medicine use during lactation in rural NSW (Table 3). 
The specific exposures in the unclassified range are detailed in Table 4 by caller type. The data 
illustrate that the most common enquiries in the unclassified category related to topical 
preparations, complementary medicines, vitamins and minerals, cold and flu preparations and 
gastrointestinal medicines. There appeared to be no difference between the two groups for type 
of medicine enquiry in this group of medications.  
Of those drugs with risk categorisations, calls regarding gastrointestinal medicines (11.2%), 
antihistamines (7.7%), antibiotics (7.35%), antivirals (7.1%), antifungals (5.7%) and 
antidepressants (5.5%) predominated from pharmacists. 
Drugs for the treatment of nausea and vomiting in pregnancy (NVP) as well as inadvertent use 
of contraceptives prior to confirmation of pregnancy (including emergency contraception)  
(75% of calls), were more common in the first trimester (68% of calls) as were antidepressants 
(49%) and antipsychotics (47%). Cold and flu and head lice and topical treatments 
predominated in the second trimester (>45%) while antifungals, antihistamines and anorectal 
medications were more frequent cause of calls in the third trimester (> 40% of calls). Over 80% 
of calls regarding non-steroidal anti-inflammatory drugs (NSAIDS) occurred in the first and 
second trimesters.  
Over the last 5 years, the proportion of calls from pharmacists regarding antivirals, 
complementary medicines and contraceptives have steadily increased. Among queries from 
referred patients calls regarding antifungals and gastro-intestinal treatments have also 
increased. Temporal trends regarding types of exposures are noted with an overall increase in 
the number of calls by pharmacists or referred by pharmacists occurring in winter months. Calls 
by pharmacists about cough and cold preparations in both pregnant and breastfeeding women 
increased in winter and calls referred by pharmacists regarding over-the-counter medications 
use in pregnancy similarly nearly doubled in winter. 
Discussion 
To the best of our knowledge this is the first detailed analysis of calls regarding medication 
exposures during pregnancy and/or breastfeeding made by pharmacists and patients referred 
by pharmacists to a Teratogen Information Service such as MotherSafe.  The data show that 
pharmacists and their patients frequently used this service.  Analysis of the pattern of calls 
indicates that the medication queries related mainly to calls during pregnancy and breastfeeding 
and rarely to the use of medications in a planned (future) pregnancy.  Medications not classified 
into the standard pregnancy categories (i.e. complementary medicines or vitamins) were the 
most frequent reason for calls to MotherSafe relating to use in pregnancy.  
Although pharmacists profess a need for succinct information 9, the A to X categorisation of 
drugs in pregnancy should not be used as the definitive resource in prescribing medications in 
pregnancy, for women planning to conceive or those breastfeeding as categories do not apply 
to the latter.  Unfortunately, however, pharmacists rely heavily upon the letter categories 
categories (which are included in prescribing references as well as in product and consumer 
medicines information) when managing pregnant patients 9. Misuse of categories can result in 
significant harm including undue anxiety due to heightened perception of risk and cessation of 
needed medications on supposed fetal safety grounds, thereby potentially compromising both 
the mother’s and baby’s health. Better training and access to evidence-based information 
sources would obviate the need for pharmacists to rely on these categories. For example, the 
AMH ceased including the pregnancy categories, opting for more relevant statements or advice 
regarding safety or otherwise of a particular medication in pregnancy. Likewise the FDA in the 
USA have abandoned their letter categories so that all new drugs now have a descriptive label 
as per the new PLLR Pregnancy and Lactation Labelling Rule (PLLR) which came into effect 
in 2014 11.In this changing environment it is critical that pharmacists and other health 
professionals develop skills in compiling a decision to recommend or not recommend a drug 
for use in pregnant/lactating women based on a thorough knowledge of first principles such as 
mechanism of teratogenic potential, drug structure /pharmacokinetics and the benefit versus 
risk of use. 
In addition, many products which pregnant women may consider taking are exempt from 
classification. These include many commonly used products such as complementary 
medicines, laxatives, diagnostic agents, many topical preparations, vitamins (other than 
vitamin A and nicotinic acid) and minerals. Most women will take at least one medication 
(prescribed or OTC) during pregnancy to treat acute or chronic illnesses 12.   
Almost twice as many patients sought more advice regarding medications with risk category 
A compared to pharmacists themselves. Although in general, clinical hesitancy about 
counselling pregnant women about drugs was subliminally evident in a previous qualitative 
study with Australian pharmacists, pharmacists in the study still appeared reasonably confident 
in counselling women about drugs in categories A, D and X, where they probably felt the 
evidence supporting the allocation of that particular category was straightforward 9. Analysis 
of MotherSafe calls in this study, reinforced this finding regarding pharmacists, confidence in 
counselling about drugs in Category A. However, as part of good practice and as a risk aversion 
strategy, most pharmacists may also provide patients with information about MotherSafe and 
encourage calls, despite their clinical confidence about the safety of using a particular drug in 
pregnancy. Alternatively, patients using drugs in Category A may be using MotherSafe as a 
second opinion to reassure themselves about the safety of drug use. This suggests perhaps that 
pharmacists training needs to ensure confidence in counselling pregnant women about 
medication use in addition to clinical knowledge on the topic. Another explanation could be 
that consumers need reassurance about all exposures (regardless of category) and do not 
necessarily take the categories into account when seeking further information about the safety 
or otherwise of any product they intend to use.  
Over half the calls referred by or from pharmacists related to exposures during pregnancy with 
one third relating to breastfeeding. Medications which had no pregnancy category comprised 
40% of pregnancy exposure calls. This suggests that although pregnant women use or consider 
using complementary medicines and vitamins/dietary supplements they worry about their 
safety, resulting in a significant proportion of calls to MotherSafe regarding these products.  
Complementary medicine use in pregnancy is well documented in the literature (although 
pregnancy safety data is extremely limited)  with perceived benefits cited by women including 
‘natural products’, self-determination and belief in a holistic approach  13, 14.  Not surprisingly 
Australian health professionals are uncertain about the safety of complementary medicines in 
pregnancy and how to source or provide appropriate information15. 
A recent qualitative study also described significant uncertainty among community 
pharmacists in providing advice to pregnant women regarding uncategorised medications 
despite being some of the main suppliers of complementary medicines 9. An analysis of 
complementary medicine use by pregnant women indicates that there is often potential for 
significant drug-herb interactions as many women also use conventional medicines, not to 
mention concerns about the purity of the compounds and paucity of evidence-based data about  
their efficacy 16. In addition, complementary products may include excipients which may have 
unknown or unanticipated side effects or interactions with prescribed medications.   Health 
professionals therefore should have the ability to relay this lack of evidence using appropriate 
risk communication skills to patients. Consultative patient communication would also be 
important so that pregnant/breastfeeding women feel secure in disclosing use of 
complementary medicines to conventional health professionals 17, 18.  
While it is likely that a significant number of women also use complementary medicines during 
breastfeeding, calls to MotherSafe suggest there are less safety concerns during breastfeeding 
than pregnancy, which is not altogether surprising.  During breastfeeding women may feel they 
have more control over an exposure for example by withholding feeds when using the 
medication. As with pregnancy, there is a lack of confidence amongst Australian health 
professionals including community pharmacists in counselling women about the use of 
complementary medicines whilst breastfeeding 19. 
While the small number of calls regarding medications with suspected or known teratogenic 
risks (Categories D and X) probably reflects the relatively low dispensing frequency in this 
population, it may also reflect pharmacists’ greater confidence in advising women in these 
higher risk categories 9.  This perhaps relates to the less ambiguous nature of the use 
information of medications in these categories.   However, there are examples of unnecessarily 
worrying counselling given to patients based on misleading categorisation eg tetracyclines20. 
There is also the need to balance risks of an untreated disease such as epilepsy in pregnancy 
with relatively small potential teratogenic risks of antiepileptic drugs such as carbamazepine 
21. 
Many calls reflected common medications that might be required regardless of pregnancy eg. 
cold and flu preparations, antihistamines, antibiotics, simple analgesics and topical 
medications. Medications for chronic conditions such as depression are also a common source 
of enquiry. Although there was no difference in the number of calls as they related to risk 
categories of drugs across the three trimesters, the type of medication did change. 
Unsurprisingly calls regarding treatment of nausea and vomiting of pregnancy were more 
common in the first trimester. Queries regarding NSAIDs were also more frequent in the first 
and second trimesters. This likely relates to the risk of this drug class on prostaglandin synthesis 
inhibition resulting in contraindication during the third trimester of pregnancy (category C).  
The median gestational age for calls regarding pregnancy was 18 (10 – 28) weeks and this is 
contrary to what one would expect given that the crucial period for potential teratogenic effects 
is 4-10 weeks of gestation. One possible explanation is that women are unaware of the 
importance of the embryonic stage of development or alternately that they sought advice from 
another source eg their family doctor about early pregnancy exposures at the time that their 
pregnancy was confirmed 22, 23.  
Preconception planning is ideal so that women with chronic conditions can switch from  
potentially teratogenic to safer medications and optimise their health and improve pregnancy 
outcomes 24.24. This could and should be incorporated into opportunistic counselling by 
pharmacists at a time when women are buying products such as ovulation or even pregnancy 
testing kits.  
The main weakness of the study is that it is an observational retrospective cohort study without 
a control group and without follow up. Clearly a significant number of calls from consumers 
were not ascertained as being referred from a pharmacist. 
This study highlights the need for community pharmacists and their clients to have access to 
reliable evidence-based information sources in order to optimise the use of prescribed 
medications, over the counter and complementary preparations during pregnancy and 
breastfeeding.  It is important that pharmacists feel comfortable in counselling patients about 
exposures in pregnancy and breastfeeding based on whatever data (albeit limited) is available 
and to be aware of and utilise or refer their patients to services such as MotherSafe and other 
Obstetric Drug Information Services. In addition, they should understand the limitations of the 
product information and consumer medicines information when advising customers about the 
safety or otherwise of exposures during pregnancy and breastfeeding. Importantly, pharmacists 
need to have the clinical skills to overlay many different clinical variables to estimate exposure 
risk in the event where specific pregnancy/lactation data is unavailable. For example, if a drug 
has minimal oral absorption known via pharmacokinetic data (eg infliximab and other 
biologics) then one can be reassured regarding use in breastfeeding. Similarly, a drug that is 
clinically used in the neonatal/ paediatric population is likely safe for use in breastfeeding 
mothers given amounts of drug an infant is likely to receive via breastmilk would be 
significantly lower than through direct administration to an infant.  
Pharmacists are uniquely placed to advise their clients about medications in pregnancy. They 
should take the opportunity to discuss pregnancy planning with their clients of childbearing 
age who are taking regular prescribed medication so that their medications can be optimised 
prior to pregnancy and other issues like supplementation with folate and prenatal multivitamins 
as well as immunisation can be discussed.  There is a need for better training of pharmacists 
about appropriate information sources and the need to use evidence–based resources such as 
AMH other than the A-X categories to advise their clients about the safety/risks of medications 
in pregnancy and breastfeeding.  
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Cold and flu 
118 (6.5%) 
Table 2 Number of enquiries relating to pregnancy by medication risk category 
Risk category Pharmacist  
(n=5,077) 
Number (%)  
Pharmacist referred  
(n=3,046) 
Number (%) 
A 684 (13.5) 792 (26.0) 
B1 387 (7.6) 248 (8.1) 
B2 386 (7.6) 225 (7.4) 
B3 623 (12.3) 316 (10.4) 
C 706 (13.9) 334 (11.0) 
D 274 (5.4) 77 (2.5) 
X 7 (0.1) 1 (0.0) 
unclassified† 2010 (39.6) 1053 (34.6) 
† Drugs which have no pregnancy classification  
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Over the counter 
165 (6.6%) 









Table 4: Number of enquiries regarding unclassified drugs and pregnancy exposure 
Class of medicine Pharmacist  
(n=2,010) 
Number (%)  
Patient enquiries  
(n=1053)  
Number (%) 
Topical 521 (25.9) 249 (23.6) 
Complementary 439 (21.8) 199 (18.9) 
Vitamins/minerals 284 (14.1) 132 (12.5) 
Over the counter 200 (10.0) 95 (9.0) 
Cold and flu 147 (7.3) 71 (6.7) 




Figure 1 Number of pharmacy-related calls to Mothersafe by year 
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